An open -label, randomized, cross-over study comparing pharmacokinetics and safety of fixed-dose combination for empaglifozin and metformin in Korean healthy subjects
Latest Information Update: 07 Nov 2022
At a glance
- Drugs Empagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 07 Nov 2022 New trial record
- 27 Sep 2022 Results presented at the 2022 American College of Clinical Pharmacology Annual Meeting